Healthcare-focused artificial intelligence platform company OpenEvidence Inc. revealed today that it has raised $210 million in new funding on a $3.5 billion valuation to expand its strategic content partnerships and scale its AI-powered clinical research tools.

Founded in 2021, OpenEvidence is focused on transforming how clinicians access and apply medical knowledge in real time. The company offers an AI-powered search and decision-support platform designed to assist doctors in making high-stakes clinical decisions at the point of care.

OpenEvidence’s platform is built on peer-reviewed medical literature from trusted sources such as the Journal of the American Medical Association, the New England Journal of Medicine and other leading journals to allow physicians to surface evidence-based insights in seconds, eliminating the inefficiencies of traditional medical databases.

The company’s primary offering is a clinician-facing AI search interface that allows users to input patient-specific questions or clinical scenarios and receive tailored, referenced answers based on the latest medical research. The system is Health Insurance Portability and Accountability Act-compliant and built for the unique demands of frontline healthcare, where decisions often need to be made in under a minute.

AI chatbots that allow users to search and research topics are hardly new, but arguably where OpenEvidence gets interesting is its strategic content partnerships with major medical publishers. The company has formal agreements with the American Medical Association, The New England Journal of Medicine, and other specialty journals to allow access to full-text, high-quality content that enhances the platform’s output. The idea is to ensure that clinicians aren’t just receiving AI-generated summaries versus engaging with a rigorously verified, continually updated body of medical evidence.

OpenEvidence’s platform is currently used across more than 10,000 hospitals and medical centers in the U.S., including by more than 40% of American physicians.

Google Ventures and Kleiner Perkins Caufield & Byers co-led the Series B round, with Sequoia Capital Operations, Coatue Management, Conviction Capital and Thrive Capital Management also participating.

Along with the funding announcement, the company also announced the wide release of OpenEvidence DeepConsult, an AI agent purpose-built for physicians. DeepConsult provides physicians with a personal, private team of Ph.D.-level, medically specialized AI agents built by OpenEvidence that are capable of conducting advanced medical research while the physician steps away, whether to see the next patient, take a lunch break, or get some rest.

“At a time when U.S. healthcare faces the dual challenges of clinician burnout and a projected physician shortfall of nearly 100,000 by 2030, the question of AI’s role in bridging the gap is paramount,” OpenEvidence founder Daniel Nadler said in a statement. “When physicians’ lives are hard, patients’ lives are harder. OpenEvidence’s commitment to building an AI copilot for clinicians is rooted in the belief that AI will be a force for good in the world, ultimately benefiting both healthcare professionals and the patients they serve.”

Image: OpenEvidence